Skip to main content

Table 5 Optic nerve-based measures in patients and controls

From: The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments

 

PATIENTS

CONTROLS

 
 

Clinically Affected

(mean, SD)

Clinically Unaffected

(mean, SD)

(mean, SD)

p*

Number of optic nerves (n)

14

6

16

-

RNFL average thickness (microns)

72.4 (12.9)

85.5 (10.2)

101.6 (12.1)

0.0093

Macular volume (mm 3 )

6.1 (0.5)

6.6 (0.3)

6.9 (0.4)

0.1211

Optic nerve area (mm 2 )

8.1 (1.3)

8.9 (1.1)

10.3 (0.8)

0.0123

Optic nerve MTR (pu)

28.4 (2.9)

31.3 (2.3)

32.9 (3.4)

0.2700

Optic nerve DTI Mean Diffusivity (×10 -3 mm 2 /s)

1.17 (0.29)

1.25 (0.26)

0.97 (0.13)

0.0145

Optic nerve DTI Fractional Anisotropy (×10 3 )

298.2 (91.2)

353.3 (88.6)

530.6 (99.7)

0.0004

Optic nerve DTI Radial Diffusivity (×10 -3 mm 2 /s)

0.99 (0.26)

1.03 (0.24)

0.67 (0.13)

0.0007

Optic nerve DTI Axial Diffusivity (×10 -3 mm 2 /s)

1.53 (0.42)

1.70 (0.35)

1.58 (0.23)

0.4809

  1. RNFL = Retinal Nerve Fibre Layer; VER = Visual Evoked Response; DTI = Diffusion Tensor Imaging. * Significance test for control vs. patient by 2-way ANOVA controlling for optic nerve status in patient group (clinically affected/unaffected)